H3.1核小体预测脓毒症患者肾脏替代治疗需求与死亡率:SISPCT随机对照试验的二次分析
该研究为SISPCT随机对照试验的二次分析,纳入德国33个ICU中971例有入院H3.1核小体数据的脓毒症与脓毒症休克患者(927例有肾脏替代治疗数据)。入院H3.1水平在脓毒症休克患者中高于脓毒症患者(中位数921.84 vs 432.71 ng/mL,p<0.001)。多变量分析显示,log10 H3.1每升高1个单位,28天死亡率增加48%(校正HR 1.48,95%CI 1.07-2.04,p=0.02);校正最大乳酸、降钙素原和C反应蛋白后,log10 H3.1每升高1个单位,28天内需肾脏替代治疗的风险增加80%(校正HR 1.8,95%CI 1.34-2.40,p<0.001)。作者结论认为入院H3.1核小体升高与死亡率和需肾脏替代治疗的急性肾损伤相关。
要点
- 脓毒症休克患者入院H3.1核小体中位数921.84 ng/mL,高于脓毒症患者的432.71 ng/mL(p<0.001)。
- 校正后log10 H3.1每升高1个单位,28天死亡率增加48%(校正HR 1.48,95%CI 1.07-2.04,p=0.02)。
- 校正最大乳酸、降钙素原和C反应蛋白后,log10 H3.1每升高1个单位,28天内需肾脏替代治疗风险增加80%(校正HR 1.8,95%CI 1.34-2.40,p<0.001)。
- 脓毒症休克合并需肾脏替代治疗的3期急性肾损伤患者H3.1水平为1832 ng/mL,高于脓毒症患者的801.4 ng/mL(p=0.01)。
适用人群与场景
- 德国33个ICU中2009年11月6日至2013年6月6日纳入的脓毒症与脓毒症休克患者,含90天随访期。
- 971例有完整入院血浆H3.1水平数据;927例有完整肾脏替代治疗需求数据。
研究设计与关键结果
- 研究类型为SISPCT随机对照试验的二次分析,样本量971例(肾脏替代治疗分析927例),来自德国33个ICU。
- 443例(45.6%)为脓毒症,520例(53.6%)为脓毒症休克。
- 入院H3.1水平脓毒症休克高于脓毒症:中位数921.84 vs 432.71 ng/mL,p<0.001。
- 28天死亡率多变量分析:log10 H3.1每升高1个单位,校正HR 1.48(95%CI 1.07-2.04,p=0.02)。
- 需肾脏替代治疗的3期急性肾损伤患者中,脓毒症休克H3.1为1832 ng/mL,高于脓毒症的801.4 ng/mL(p=0.01)。
- 校正最大乳酸、降钙素原和C反应蛋白后,log10 H3.1每升高1个单位,28天内需肾脏替代治疗的校正HR 1.8(95%CI 1.34-2.40,p<0.001)。
证据类型、等级与局限
- 证据类型:大型多中心随机对照试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为入院H3.1核小体升高与死亡率和需肾脏替代治疗的急性肾损伤相关,原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The release of neutrophil extracellular traps is a key immune host defense mechanism that can contribute to organ damage during sepsis if excessive. We evaluated presentation H3.1 nucleosome levels in patients with sepsis, septic shock, and sepsis-associated acute kidney injury (AKI). We sought to determine if plasma H3.1 nucleosome levels could serve as predictive biomarkers for both renal replacement therapy (RRT) requirements and 28-day mortality.
DESIGN: A secondary analysis of prospectively collected samples from the large multicenter Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients with Severe Sepsis or Septic Shock (SISPCT) trial.
SETTING: Patients from 33 ICUs in Germany recruited between November 6, 2009, and June 6, 2013, including a 90-day follow-up period.
PATIENTS: A total of 971 patients with complete data on plasma H3.1 admission levels with sepsis and septic shock, and 927 patients with complete data on RRT requirements.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We evaluated associations between H3.1 levels and mortality and the time to commencement of RRT using multivariable Cox regression. A total of 443 patients (45.6%) presented with sepsis, and 520 patients (53.6%) had septic shock. Admission H3.1 levels were higher in patients with septic shock than sepsis (median, 921.84 vs. 432.71 ng/mL; p < 0.001). In a multivariable analysis for 28-day mortality, a one unit increase in log10 H3.1 levels was associated with a 48% increase in 28-day mortality (adjusted hazard ratio [HR], 1.48, 95% CI, 1.07-2.04; p = 0.02). Plasma H3.1 was also higher in patients with stage 3 AKI requiring RRT with septic shock vs. sepsis (1832 vs. 801.4 ng/mL; p = 0.01). In a multivariable Cox regression controlling for maximum lactate, procalcitonin, and C-reactive protein levels, plasma H3.1 levels were significantly higher in patients who developed AKI requiring RRT when compared with patients who did not develop AKI, with one log10 increase of H3.1 increasing the risk of 28-day RRT by 80% (adjusted HR, 1.8; 95% CI, 1.34-2.40; p < 0.001).
CONCLUSIONS: Elevated levels of H3.1 nucleosomes at admission are associated with mortality and AKI requiring RRT.
TRIAL REGISTRATION: The trial was registered in clinicaltrials.gov , identifier: NCT00832039.
参考来源
- Neumann C, Bloos F, Hla TTW, et al. H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis-A Secondary Analysis of the SISPCT Randomized Control Trial. Crit Care Med. 2026. PMID: 42545097. doi:10.1097/CCM.0000000000007270
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。